Department of Physiology, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, USA.
Auton Neurosci. 2011 Dec 7;165(2):178-90. doi: 10.1016/j.autneu.2011.07.009. Epub 2011 Aug 30.
Both delayed gastrointestinal transit and autonomic neuropathy have been documented in patients with diabetes mellitus. The mechanism of neostigmine, an agent that mimics release of acetylcholine from autonomic neurons by prokinetic agents, to contract smooth muscle, despite dysfunctional enteric neural pathways, was determined using isolated ilea from STZ-treated and control guinea pigs. Both bethanechol- and neostigmine-induced contractions were stronger in diabetic ileum. Bethanechol-induced contractions of control but not diabetic ileum were increased by low dose scopolamine suggesting reduced activation of presynaptic muscarinic autoreceptors in diabetic ileum. The muscarinic receptor antagonist 4-DAMP strongly, but the nicotinic receptor antagonist hexamethonium only weakly, reduced neostigmine-induced contractions of control and diabetic ilea. The amount of acetylcholine, inferred from tissue choline content, was increased in diabetic ileum. Nicotinic neural and noncholinergic postjunctional smooth muscle receptors contributed more strongly to neostigmine-induced contractions in diabetic than control ileum. Relaxation of diabetic ileum by exogenous nitric oxide generated from sodium nitroprusside was comparable to control ileum, but smooth muscle relaxation by l-arginine using neuronal nitric oxide synthase to generate nitric oxide was weaker in diabetic ileum with evidence for a role for inducible nitric oxide synthase. Despite autonomic neuropathy, neostigmine strongly contracted ileum from diabetic animals but by a different mechanism including stronger activation of postjunctional muscarinic receptors, greater synaptic acetylcholine, stronger activation of noncholinergic excitatory pathways, and weaker activation of inhibitory pathways. A selective medication targeting a specific neural pathway may more effectively treat disordered gastrointestinal transit in patients with diabetes mellitus.
糖尿病患者既存在胃肠道转运延迟,也存在自主神经病变。尽管肠神经通路功能障碍,但新斯的明(一种通过促动力药物模拟自主神经元释放乙酰胆碱的药物)仍能使平滑肌收缩的机制,是通过 STZ 处理和对照豚鼠的分离回肠来确定的。无论是在糖尿病回肠中,还是在对照回肠中,新斯的明和贝那胆碱诱导的收缩均更强。低剂量东莨菪碱可增强对照回肠而非糖尿病回肠中贝那胆碱诱导的收缩,提示糖尿病回肠中存在前膜毒蕈碱自身受体的激活减少。毒蕈碱受体拮抗剂 4-DAMP 强烈,但烟碱受体拮抗剂六烃季铵仅弱,减少了对照和糖尿病回肠中由新斯的明诱导的收缩。从组织胆碱含量推断,乙酰胆碱的量在糖尿病回肠中增加。在糖尿病回肠中,烟碱能神经和非胆碱能突触后平滑肌受体对新斯的明诱导的收缩的贡献比对照回肠更强。与对照回肠相比,外源性一氧化氮(由硝普钠生成)可使糖尿病回肠松弛,但使用神经元型一氧化氮合酶生成一氧化氮的 l-精氨酸使糖尿病回肠松弛的作用较弱,表明诱导型一氧化氮合酶发挥作用。尽管存在自主神经病变,但新斯的明仍可强烈收缩糖尿病动物的回肠,但作用机制不同,包括后膜毒蕈碱受体的激活增强、突触乙酰胆碱增加、非胆碱能兴奋性通路的激活增强以及抑制性通路的激活减弱。针对特定神经通路的选择性药物可能更有效地治疗糖尿病患者的胃肠道转运障碍。